Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. (Q38171376)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

title

Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

author name string

Roberto García-Figueiras

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Cristina Suárez

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Antonia Arjonilla

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Javier Puente

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Blanca Vargas

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Maria José Méndez Vidal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

Carmen Sebastiá

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

publication date

12 December 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

3 March 2020

page(s)

9-24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s11523-013-0304-7

3 March 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Renal-cell carcinoma--molecular pathways and therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

New insights into the biology of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Mutations of the VHL tumour suppressor gene in renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Targeted therapies in renal cell cancer: recent developments in imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Sorafenib in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Neoadjuvant temsirolimus effectiveness in downstaging advanced non-clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal c

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Imaging in the follow-up of renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Multiphase contrast-enhanced helical CT of liver metastases from renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Do imaging biomarkers relate to outcome in patients treated with VEGF inhibitors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Optimizing the size variation threshold for the CT evaluation of response in metastatic renal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Optimisation of the tumour response threshold in patients treated with everolimus for metastatic renal cell carcinoma: analysis of response and progression-free survival in the RECORD-1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Serum lactate dehydrogenase predicts for overall survival benefit in patients with metastatic renal cell carcinoma treated with inhibition of mammalian target of rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Response assessment classification in patients with advanced renal cell carcinoma treated on clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Personalized tumor response assessment in the era of molecular medicine: cancer-specific and therapy-specific response criteria to complement pitfalls of RECIST

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Multidisciplinary team working across different tumour types: analysis of a national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Novel oncologic drugs: what they do and how they affect images.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Radiologic measurements of tumor response to treatment: practical approaches and limitations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Evaluation of treatment response in patients with metastatic renal cell carcinoma: role of state-of-the-art cross-sectional imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Metastatic renal cell carcinoma: relationship between initial metastasis hypoxia, change after 1 month's sunitinib, and therapeutic response: an 18F-fluoromisonidazole PET/CT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Imaging vascular function for early stage clinical trials using dynamic contrast-enhanced magnetic resonance imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Current status and guidelines for the assessment of tumour vascular support with dynamic contrast-enhanced computed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Computed tomography perfusion imaging for therapeutic assessment: has it come of age as a biomarker in oncology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

CT perfusion in oncologic imaging: a useful tool?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Angiogenesis of renal cell carcinoma: perfusion CT findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Diffusion MR imaging for monitoring of treatment response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Functional MRI techniques demonstrate early vascular changes in renal cell cancer patients treated with sunitinib: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Whole-body MRI in follow-up of patients with renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

PET Imaging of Integrin αVβ3 Expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Imaging key biomarkers of tumor angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Comparison of integrin alphaVbeta3 expression and glucose metabolism in primary and metastatic lesions in cancer patients: a PET study using 18F-galacto-RGD and 18F-FDG.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

Synthesis of [18F]SU11248, a new potential PET tracer for imaging cancer tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11523-013-0304-7

To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound

21 January 2018

1 reference

12 December 2020

[Reliability of the response rate in oncology: analysis of the causes for variation]

1 reference

12 December 2020

Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy.

1 reference

12 December 2020

Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer

1 reference

12 December 2020

Dynamic contrast enhanced ultrasound assessment of the vascular effects of novel therapeutics in early stage trials

1 reference

12 December 2020

[Measurement of tumour response to cancer treatment: morphologic imaging role]

1 reference

12 December 2020

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

1 reference

12 December 2020

Is dual-phase abdominal CT necessary for the optimal detection of metastases from renal cell carcinoma?

1 reference

12 December 2020

Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis

1 reference

12 December 2020

Targeted therapy in renal cell carcinoma: moving from molecular agents to specific immunotherapy

1 reference

12 December 2020

Multidisciplinarity and medical decision, impact for patients with cancer: sociological assessment of two tumour committees' organization

1 reference

12 December 2020

Molecular aspects of renal cell carcinoma: a review

1 reference

12 December 2020

10.1007/S11523-013-0304-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

3 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24338498%20AND%20SRC:MED&resulttype=core&format=json